Melatonin and arterial hypertension: from understanding pathogenesis to therapeutic modalities
Abstract
Biological rhythms are driven by the hypothalamic circadian pacemaker. Its action is mediated through epiphyseal melatonin that transmits regulatory signals directly to target organs. Circadian fluctuations of arterial pressure suggest participation of melatonin in regulation of this important indicator of cardiovascular activity. Melatonin is a key endogenous hypotensive factor. Some studies demonstrated that additional prescription ofmelatonin to patients with nocturnal hypertension refractory to traditional hypotensive agents significantly lowered arterial pressure during sleep. Moreover, melatonin was shown to exert meteo- and magnetoprotective action and thereby reduce the dependence ofpatients with arterial hypertension on the adverse environmental factors.
Read the paper
Related studies
- A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials Evaluating the Evidence Base of Melatonin, Light Exposure, Exercise, and Complementary and Alternative Medicine for Patients with Insomnia Disorder
- Use of Melatonin and/on Ramelteon for the Treatment of Insomnia in Older Adults: A Systematic Review and Meta-Analysis
- Influence of evening light exposure on polysomnographically assessed night-time sleep: A systematic review with meta-analysis
- Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation
- Significant potential of melatonin therapy in Parkinson’s disease – a meta-analysis of randomized controlled trials
- Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.